Welcome to our dedicated page for Eagle Pharmaceut news (Ticker: EGRX), a resource for investors and traders seeking the latest updates and insights on Eagle Pharmaceut stock.
Eagle Pharmaceuticals, Inc. reports developments tied to its specialty pharmaceutical portfolio, research and development programs, and public-company governance. The company combines research and development, clinical, manufacturing, and commercial capabilities, with commercialized products including PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® in Japan, and BYFAVO® through Acacia Pharma Inc. Its pipeline is described around oncology and CNS/metabolic critical care product candidates.
Recurring Eagle news includes portfolio actions such as the U.S. Barhemsys marketing-authorization divestiture, availability of audited and unaudited financial statements, annual meeting materials and voting results, board and stockholder matters, and amendments to its limited-duration stockholder rights plan.
Eagle Pharmaceuticals (EGRX) announced that CEO Scott Tarriff and CFO Brian Cahill will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 4:30 PM ET. The presentation will be held virtually, and interested parties can access the webcast here. The webcast will remain available for 30 days on the company’s website, under the Investors section.
Eagle Pharmaceuticals specializes in developing innovative medicines with a strong pipeline in oncology and CNS/metabolic critical care.
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) announced that the FDA has confirmed the company’s 180 days of marketing exclusivity for its approved abbreviated new drug application (ANDA) for vasopressin. In August, a favorable ruling from the U.S. District Court for Delaware determined that Eagle's vasopressin product does not infringe any patents asserted by Par Pharmaceutical, although an appeal is pending. CEO Scott Tarriff expressed optimism about the 2022 launch of both vasopressin and PEMFEXY™ starting February 1, 2022.
Eagle Pharmaceuticals, Inc. (EGRX) announced that Par Pharmaceutical, Inc. has withdrawn its request for a temporary restraining order against the launch of Eagle's vasopressin product. This follows a ruling by the U.S. District Court in Delaware on August 31, 2021, stating that the product does not infringe Par's asserted patents. Eagle's CEO, Scott Tarriff, expressed optimism regarding their launch plans for the vasopressin product.
Eagle Pharmaceuticals, Inc. (EGRX) announced FDA approval for its abbreviated new drug application (ANDA) for vasopressin, positioning it as a generic alternative to Vasostrict®, which generated $786 million in U.S. sales in 2020. This approval follows a favorable court ruling that confirmed no patent infringement by Eagle. With an anticipated 180-day marketing exclusivity, the company aims to enhance its critical care portfolio, which is crucial for patients and healthcare providers. The launch plans for vasopressin are now being implemented.
Eagle Pharmaceuticals (NASDAQ: EGRX) announced that CEO Scott Tarriff and CFO Brian Cahill will present at the Piper Sandler 33rd Annual Healthcare Conference on November 22, 2021, at 10:00 AM ET. Attendees can access the on-demand webcast via the company's website for 90 days post-event. Additionally, Eagle will hold one-on-one meetings on December 1, 2021, which must be requested through Piper Sandler. Eagle focuses on developing innovative medicines and has products including RYANODEX®, BENDEKA®, and BELRAPZO®.
Eagle Pharmaceuticals reported a Q3 2021 net loss of $5.6 million, or $0.43 per share, a decline from a net income of $7.1 million in Q3 2020. Total revenue decreased to $39.9 million, down from $49.9 million year-over-year, primarily due to lower sales of BELRAPZO and BENDEKA. Adjusted non-GAAP net income was $7.5 million, down from $16.1 million in the previous year. Eagle is preparing for key product launches, including vasopressin and PEMFEXY, and secured a worldwide licensing agreement for CAL02, an antitoxin agent ready for Phase 2b/3 development.
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) will release its 2021 third quarter financial results on November 9, 2021, before the market opens. CEO Scott Tarriff and CFO Brian Cahill will host a conference call on the same day at 8:30 a.m. ET to discuss the results. Investors can access the call via a toll-free U.S. number or internationally, as well as through a live and archived webcast available on the company's website. Eagle Pharmaceuticals is dedicated to innovative medicine development, with a portfolio including RYANODEX® and BENDEKA®.
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) will host an investor event on September 9, 2021, at 8:30 A.M. EDT. Led by CEO Scott Tarriff and CMO Judi Ng-Cashin, the event will discuss the CAL02 opportunity and the current landscape for treating severe pneumonia. CAL02 is an innovative drug that targets bacterial toxins, potentially reducing complications in pneumonia patients without contributing to antibiotic resistance. Additional details, including a webcast link, are available on the company’s website.
Eagle Pharmaceuticals, Inc. (EGRX) has announced that CEO Scott Tarriff and CFO Brian Cahill will present at two upcoming investor conferences. The first is the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, at 2:00 p.m. ET, with a live webcast available here. The second conference is the 2021 Cantor Virtual Global Healthcare Conference on September 28, 2021, at 4:40 p.m. ET, with a live webcast available here.
Eagle Pharmaceuticals (NASDAQ: EGRX) has achieved a significant legal victory as the U.S. District Court for the District of Delaware ruled that its proposed vasopressin product does not infringe any patents asserted by Par. The ruling allows Eagle to continue its plans to market a generic version of Vasostrict, which generated $786 million in U.S. sales in 2020. CEO Scott Tarriff expressed optimism about providing a generic alternative, emphasizing its importance for public access. The court's decision does not address Eagle's claims regarding the invalidity of Par's patents.